Explain the Role of Vilobelimab, the Latest MAb for COVID-19

A new emergency use authorization will put the spotlight on vilobelimab (Gohibic) to treat COVID-19 in hospitalized adults.

Vilobelimab blocks complement C5a...to reduce inflammation.

It’s only authorized to treat COVID-19 when started within 48 hours after beginning mechanical ventilation or extracorporeal membrane oxygenation (ECMO).

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote